- Home
- DGX
as of 02-25-2026 12:17pm EST
$206.47
$3.07
-1.47%
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | SECAUCUS |
| Market Cap: | 21.2B | IPO Year: | 1996 |
| Target Price: | $208.62 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | monthly | |
| EPS: | 6.57 | EPS Growth: | 2.67 |
| 52 Week Low/High: | $157.20 - $213.20 | Next Earning Date: | 05-11-2026 |
| Revenue: | $9,872,000,000 | Revenue Growth: | 6.70% |
| Revenue Growth (this year): | 7.09% | Revenue Growth (next year): | 3.70% |
| P/E Ratio: | 31.89 | Index: | |
| Free Cash Flow: | 909.0M | FCF Growth: | +49.51% |
AI-Powered DGX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 68.55%
68.55%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Quest Diagnostics Incorporated (DGX)
Plewman Patrick
Sell
SVP for Diagnostic Services
DGX Feb 19, 2026
Avg Cost/Share
$204.83
Shares
958
Total Value
$196,227.14
Owned After
15,838
SEC Form 4
Doherty Catherine T.
Sell
EVP, Regional Businesses
DGX Feb 19, 2026
Avg Cost/Share
$204.83
Shares
1,433
Total Value
$293,521.39
Owned After
68,402
SEC Form 4
PREVOZNIK MICHAEL E
Sell
SVP & General Counsel
DGX Feb 19, 2026
Avg Cost/Share
$204.83
Shares
1,111
Total Value
$227,566.13
Owned After
38,371
SEC Form 4
Doherty Catherine T.
Sell
EVP, Regional Businesses
DGX Feb 13, 2026
Avg Cost/Share
$207.19
Shares
26,165
Total Value
$5,393,814.70
Owned After
68,402
Plewman Patrick
Sell
SVP for Diagnostic Services
DGX Feb 10, 2026
Avg Cost/Share
$204.00
Shares
5,662
Total Value
$1,155,048.00
Owned After
15,838
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Plewman Patrick | DGX | SVP for Diagnostic Services | Feb 19, 2026 | Sell | $204.83 | 958 | $196,227.14 | 15,838 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 19, 2026 | Sell | $204.83 | 1,433 | $293,521.39 | 68,402 | |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Feb 19, 2026 | Sell | $204.83 | 1,111 | $227,566.13 | 38,371 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 13, 2026 | Sell | $207.19 | 26,165 | $5,393,814.70 | 68,402 | |
| Plewman Patrick | DGX | SVP for Diagnostic Services | Feb 10, 2026 | Sell | $204.00 | 5,662 | $1,155,048.00 | 15,838 |
Latest Quest Diagnostics Incorporated News
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
Simply Wall St.
Guardant Health Expands Cancer Testing Platform With MetaSight Deal And Shield Growth
📊
AI Sentiment
Positive
7/10
MT Newswires
Piper Sandler Adjusts Price Target on Quest Diagnostics to $215 From $200, Maintains Neutral Rating
📊
AI Sentiment
Positive
7/10
Compare DGX vs Leading Stocks
See how DGX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.